Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: A retrospective analysis spanning 20 years

Liver International

Volumn 28, Issue 1, 2008, Pages 72-78

  Yilmaz, Nevin ^a   Shiffman, Mitchell L ^a   Todd Stravitz, R ^a   Sterling, Richard K ^a   Luketic, Velimir A ^a   Sanyal, Arun J ^a   Maluf, Daniel ^a   Coterell, Adrian ^a   Posner, Marc P ^a   Fisher, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adefovir dipivoxil; HBIG; Hepatitis B virus; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS E ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS B; HIGH RISK PATIENT; HUMAN; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; RECURRENT VIRUS INFECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RECURRENCE; RETROSPECTIVE STUDIES; VIRGINIA;

EID: 37449018528     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01611.x     Document Type: Article

References (28)

1. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
2. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
3. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
4. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
6. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
7. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-7.
8. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
9. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
10. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-11.
11. Luketic VA, Shiffman ML, McCall JB, Posner MP, Mills AS, Carithers RL Jr. Primary hepatocellular carcinoma after orthotopic liver transplantation for chronic hepatitis B infection. Ann Intern Med 1991; 114: 212-3.
12. Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13: 90-6.
13. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-5.
14. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-64.
15. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
16. Schreibman IR, Schiff ER. Prevention and treatment of recurrent hepatitis B after liver transplantation: The current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006; 5: 8.
17. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
18. Luketic VA, Shiffman ML, Sanyal AJ, et al. Long term low dose passive immunoprophylaxsis with HBIG effectively prevents recurrence of hepatitis B infection after liver transplantation. Transplantation 1998; S49.
19. Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol 1994; 32: 2088-91.
20. Bowden S. Serological and molecular diagnosis. Semin Liver Dis 2006; 26: 97-103.
21. Han SH, Ofman J, holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-8.
22. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182-7.
23. Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000; 70: 809-15.
24. Malkan G, Cattral M, Humar A, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69: 1403-7.
25. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-7.
26. Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888-94.
27. Terrault N, Roche B, Didier SD. Management of the hepatitis B virus in the liver transplant setting: A European and an American perspective. Liver Transpl 2005; 11: 716-3.
28. Kruger M. European hepatitis B immunoglobulin trials: Prevention of recurrent hepatitis B after liver transplantation. Clin Transpl 2000; 14 (Suppl. 2): 14-9.